Beta-blockers (Carvedilol, Metoprolol succinate)
Treatment for Heart Failure
Typical Dosage: Carvedilol 3.125 mg BID up to 25-50 mg BID; Metoprolol succinate 12.5-25 mg daily up to 200 mg daily
Effectiveness
83%
Safety Score
70%
Clinical Trials
16
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Carvedilol 3.125 mg BID up to 25-50 mg BID; Metoprolol succinate 12.5-25 mg daily up to 200 mg daily
Time to Effect
3-6 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
35(Treat 35 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$600
Side Effect Mgmt:$50
Total Annual:$850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$1,545
Comparison vs No treatment
Cost Difference
$-1,000/year
Less expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Beta-blockers (Carvedilol, Metoprolol succinate) Outcomes
for Heart Failure
Efficacy Outcomes
Overall Effectiveness
+83%
Response Rate
+55%
Common Side Effects
Fatigue
+15%
Bradycardia
+8%
Hypotension
+7%
Dizziness
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
7 active trials recruiting for Beta-blockers (Carvedilol, Metoprolol succinate) in Heart Failure
Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction
NCT04996550NOT YET RECRUITING
5.6K participants
OBSERVATIONAL
Odense, Denmark
Started: Jan 3, 2022
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
NCT07298993ENROLLING BY INVITATIONPHASE4
240 participants
INTERVENTIONAL
Pleasanton, United States
Started: Feb 2, 2026
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT06964464RECRUITINGPHASE4
2K participants
INTERVENTIONAL
Scottsdale, United States +12 more
Started: Aug 17, 2025
A Preliminary Study for INFORMED
NCT05585125ENROLLING BY INVITATIONPHASE4
20 participants
INTERVENTIONAL
New York, United States
Started: Feb 7, 2024
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
NCT05019027ENROLLING BY INVITATIONPHASE4
20 participants
INTERVENTIONAL
New York, United States
Started: Jan 31, 2024
Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction
NCT06518694RECRUITINGPHASE3
1.3K participants
INTERVENTIONAL
Paris, France
Started: Feb 11, 2025
Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial
NCT07238452NOT YET RECRUITINGPHASE4
1.06K participants
INTERVENTIONAL
Started: Dec 1, 2025
Completed Clinical Trials
7 completed trials for Beta-blockers (Carvedilol, Metoprolol succinate) in Heart Failure
Impact of Beta-blockers on Physical Function in HFpEF
NCT04767061COMPLETEDPHASE4
9 participants
INTERVENTIONAL
New York, United States
Started: Apr 1, 2021
Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF
NCT04757584COMPLETEDPHASE4
9 participants
INTERVENTIONAL
New York, United States
Started: Apr 1, 2021
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
NCT02200822COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Genk, Belgium
Started: Jul 1, 2014
Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure
NCT00497003COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Copenhagen, Denmark
Started: Feb 1, 2004
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675COMPLETEDPHASE4
78 participants
INTERVENTIONAL
Taipei, Taiwan
Started: May 29, 2020
The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure
NCT01971944COMPLETED
50 participants
OBSERVATIONAL
Chapel Hill, United States
Started: Dec 1, 2010
Curing Atrial Fibrillation in Heart Failure
NCT00292162COMPLETEDNA
41 participants
INTERVENTIONAL
Glasgow, United Kingdom
Started: Jan 1, 2007